Latest market price reference for Baricitinib

Baricitinib is a selective JAK1 and JAK2 tyrosine kinase inhibitor, mainly used to treat moderately to severely active rheumatoid arthritis (RA), especially for patients with poor response to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). By inhibiting the JAK-STAT signaling pathway, the drug reduces the release of inflammatory mediators, controls abnormal activation of the immune system, reduces joint pain, swelling and inflammation progression, and delays joint structural destruction. In clinical practice, baricitinib not only improves patients' symptoms, but also improves their quality of life and enables patients to resume daily activities.

In the domestic market, baricitinib has been launched and is covered by medical insurance, which means that patients can purchase it through regular medical institutions. However, because it is an original and innovative drug, the price is still relatively high. The actual amount paid after specific reimbursement varies due to differences in regional medical insurance policies. Patients should consult the pharmacy of their hospital to obtain accurate information. For patients who require long-term maintenance treatment, medical insurance reimbursement can reduce the financial burden to a certain extent.

There are also some generic versions of baricitinib in overseas markets, mainly produced by Bangladesh General Pharmaceutical Factory. The ingredients of generic drugs are the same as the original drugs, but the price is more economical, usually around more than 200 yuan, making it easier for some patients with limited financial conditions to use them for a long time. While ensuring efficacy and safety, generic drugs also provide more accessible options for rheumatoid arthritis patients around the world. Clinically, both original drugs and verified generic drugs must be used under the guidance of professional doctors to ensure reasonable dosage and safety, combined with regular laboratory monitoring to prevent potential adverse reactions, such as hematological abnormalities, infection risks, or abnormal liver and kidney function.

In addition to rheumatoid arthritis, studies have also shown that baricitinib has potential application value in other autoimmune diseases or inflammation-related diseases, expressing its broad prospects in the field of immune regulation.

Reference materials:https://go.drugbank.com/drugs/DB11817